Cargando…

Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit

INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Tempia Valenta, Silvia, Stecchi, Michele, Perazza, Federica, Nuccitelli, Chiara, Villanova, Nicola, Pironi, Loris, Atti, Anna Rita, Petroni, Maria Letizia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684642/
https://www.ncbi.nlm.nih.gov/pubmed/38015342
http://dx.doi.org/10.1007/s40519-023-01625-5
_version_ 1785151448706711552
author Tempia Valenta, Silvia
Stecchi, Michele
Perazza, Federica
Nuccitelli, Chiara
Villanova, Nicola
Pironi, Loris
Atti, Anna Rita
Petroni, Maria Letizia
author_facet Tempia Valenta, Silvia
Stecchi, Michele
Perazza, Federica
Nuccitelli, Chiara
Villanova, Nicola
Pironi, Loris
Atti, Anna Rita
Petroni, Maria Letizia
author_sort Tempia Valenta, Silvia
collection PubMed
description INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS: A clinical audit was carried out on a cohort of 54 adults with obesity treated with liraglutide 3.0 mg. We retrospectively analyzed the connection between psychiatric symptoms assessed through the State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), and Binge Eating Scale (BES). Adherence to therapy was assessed by the maximum dosage (MD) and treatment duration (TD). RESULTS: Notably, a discontinuation rate of 59% was encountered. However, among those who continued the treatment, we observed a negative association between anxiety symptoms (STAI score) and MD, depression symptoms (BDI score) and TD, and a higher likelihood of binge eating (BES score > 17) and TD. Moreover, presence of psychiatric symptoms did not compromise drug's effectiveness in achieving weight loss, which was 4.43% (± 5.5 SD) in the whole sample and 5.3% (± 6.3 SD) in the subgroup evaluated at 12 weeks. CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges. LEVEL OF EVIDENCE: Level V, descriptive studies.
format Online
Article
Text
id pubmed-10684642
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-106846422023-11-30 Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit Tempia Valenta, Silvia Stecchi, Michele Perazza, Federica Nuccitelli, Chiara Villanova, Nicola Pironi, Loris Atti, Anna Rita Petroni, Maria Letizia Eat Weight Disord Research INTRODUCTION: Liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) analogue, is a medication approved for obesity treatment. This study aimed to investigate the relationship between psychiatric symptoms, including depression, anxiety, and binge eating, and their impact on therapy adherence. METHODS: A clinical audit was carried out on a cohort of 54 adults with obesity treated with liraglutide 3.0 mg. We retrospectively analyzed the connection between psychiatric symptoms assessed through the State-Trait Anxiety Inventory (STAI), Beck Depression Inventory (BDI), and Binge Eating Scale (BES). Adherence to therapy was assessed by the maximum dosage (MD) and treatment duration (TD). RESULTS: Notably, a discontinuation rate of 59% was encountered. However, among those who continued the treatment, we observed a negative association between anxiety symptoms (STAI score) and MD, depression symptoms (BDI score) and TD, and a higher likelihood of binge eating (BES score > 17) and TD. Moreover, presence of psychiatric symptoms did not compromise drug's effectiveness in achieving weight loss, which was 4.43% (± 5.5 SD) in the whole sample and 5.3% (± 6.3 SD) in the subgroup evaluated at 12 weeks. CONCLUSION: We observed a high discontinuation rate in real-life clinical setting, where Liraglutide 3.0 therapy is paid out-of-pocket. While psychiatric symptoms might play a role in diminishing adherence to therapy, they do not prevent drug's effectiveness to promote weight loss. This finding underscores the potential advantages of liraglutide 3.0 mg therapy for individuals contending with obesity while simultaneously managing mental health challenges. LEVEL OF EVIDENCE: Level V, descriptive studies. Springer International Publishing 2023-11-28 2023 /pmc/articles/PMC10684642/ /pubmed/38015342 http://dx.doi.org/10.1007/s40519-023-01625-5 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Research
Tempia Valenta, Silvia
Stecchi, Michele
Perazza, Federica
Nuccitelli, Chiara
Villanova, Nicola
Pironi, Loris
Atti, Anna Rita
Petroni, Maria Letizia
Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
title Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
title_full Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
title_fullStr Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
title_full_unstemmed Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
title_short Liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? Insights from a clinical audit
title_sort liraglutide 3.0 mg and mental health: can psychiatric symptoms be associated to adherence to therapy? insights from a clinical audit
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10684642/
https://www.ncbi.nlm.nih.gov/pubmed/38015342
http://dx.doi.org/10.1007/s40519-023-01625-5
work_keys_str_mv AT tempiavalentasilvia liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit
AT stecchimichele liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit
AT perazzafederica liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit
AT nuccitellichiara liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit
AT villanovanicola liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit
AT pironiloris liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit
AT attiannarita liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit
AT petronimarialetizia liraglutide30mgandmentalhealthcanpsychiatricsymptomsbeassociatedtoadherencetotherapyinsightsfromaclinicalaudit